ライフサイエンスコーパス: fentanyl

1 locomotor stimulant response to both MA and fentanyl.

2 ensitivity to the mu-opioid receptor agonist fentanyl.

3 hosphorylation) blocked ERK1/2 activation by fentanyl.

4 a reduced the clearance and/or metabolism of fentanyl.

5 ions than ketamine combined with propofol or fentanyl.

6 The hair of one employee was tested for fentanyl.

7 entanyl; his hair sample tested positive for fentanyl.

8 d analgesia with potent opioid drugs such as fentanyl.

9 nction of opioid drugs, such as morphine and fentanyl.

10 n of proteins that bind the potent analgesic fentanyl.

11 Strategy for Transmucosal Immediate-Release Fentanyl.

12 ed with differences in sensitivity to MA and fentanyl.

13 sult in more rapid recovery as compared with fentanyl.

14 sing doses of the mu-opioid receptor agonist fentanyl (0, 0.0004, 0.004, and 0.04 mg/kg) were systemi

15 ane (300 mum) significantly inhibited, while fentanyl (1 mum) significantly enhanced, EPSC amplitude

16 with either isoflurane (1% by inhalation) or fentanyl (10 mcg/kg iv bolus then 50 mcg/kg/h infusion).

17 e rats were randomized to isoflurane (1%) or fentanyl (10 mcg/kg iv bolus then 50 mcg/kg/h) for 30 mi

18 chanically ventilated, and anesthetized with fentanyl (10 microg/kg intravenous bolus and then 50 mic

19 use of morphine (59%; 2.2 to 3.5 million g), fentanyl (1168%; 3263 to 41,371 g), oxycodone (23%; 1.6

20 ssociated with a significantly lower dose of fentanyl (165.0 microg [RF group] vs 75.0 microg [cryoab

21 am (NaCl, interspinous L(3)-L(4)) or active (fentanyl 25 mug, intrathecal L(3)-L(4)) spinal anesthesi

22 ically increased by morphine (2-fold) and by fentanyl (3.8-fold).

23 The combinations of ketamine and fentanyl (4.1%; OR, 4.0; 95% CI, 1.8-8.1) and ketamine a

24 orted as the most frequently used sedatives; fentanyl (44%) and morphine (20%) the most frequent opio

25 sions of midazolam (59% vs. 32%, p < .05) or fentanyl (57% vs. 32%, p < .05) and physical soft-limb r

26 1335 to 806), oxycodone (29%; 4526 to 3190), fentanyl (59%; 59 to 24), and hydromorphone (15%; 718 to

27 mia decreased the systemic clearance of both fentanyl (61.5 +/- 11.5 to 48.9 +/- 8.95 mL/min/kg; p <

28 antly prolonged after spinal anesthesia with fentanyl (639 +/- 87 s vs. 423 +/- 38 s [mean +/- SEM];

29 ew years we and others have used intrathecal fentanyl, a mu-opiate receptor agonist, in humans to red

30 in juvenile rats, where by administration of fentanyl, a selective mu-opiate agonist, and induction o

31 tion of central motor output via intrathecal fentanyl: (a) reduced the mean arterial blood pressure (

32 man morbidity and mortality linked to acetyl fentanyl abuse.

33 In contrast, agonists such as etorphine and fentanyl activated ERKs in a beta-arrestin-dependent man

34 These results demonstrate that fentanyl acts on micro-opioid receptors on cardiac vagal

35 Fentanyl altered evoked potential waveforms slightly but

36 elationship data reported on a wide range of fentanyl analogues.

37 es with cross-reactivity for a wide panel of fentanyl analogues.

38 conscious sedation consisted of 50 microg of fentanyl and 1 mg of midazolam administered intravenousl

39 equivalent to that of the mu-opioid agonists fentanyl and [D-Ala(2),N-Me-Phe(4),Gly(5)-ol]-enkephalin

40 anyl contained high concentrations of acetyl fentanyl and acetyl norfentanyl.

41 Patients receiving fentanyl and benzodiazepines had generally weaker respon

42 this report we tested the opiate anesthetic fentanyl and compared hearing thresholds in immobilized

43 In a multivariate analysis, receipt of fentanyl and exposure to the two respiratory therapists

44 or the simultaneous quantification of acetyl fentanyl and its predicted metabolite, acetyl norfentany

45 The mean daily dosing of fentanyl and lorazepam decreased after the intervention.

46 iazepines were converted to their respective fentanyl and lorazepam equivalent units based on potency

47 in situ in rats that were anesthetized with fentanyl and mechanically ventilated.

48 actions of other opioid analgesics, such as fentanyl and methadone.

49 Time to first coma was associated with fentanyl and midazolam doses (p=0.03 and p=0.01, respect

50 Coma is associated with fentanyl and midazolam exposure; delirium is unrelated t

51 Bolus dosing of fentanyl and midazolam fails to reduce the intracranial

52 pothermia reduces the systemic clearances of fentanyl and midazolam in rats after cardiac arrest thro

53 Fentanyl and midazolam were independently administered b

54 pothermia on the in vivo pharmacokinetics of fentanyl and midazolam, two clinically relevant cytochro

55 atient-controlled intravenous analgesia with fentanyl and midazolam.

56 In addition, activation of ERK1/2 by fentanyl and morphine was rescued in GRK3-/- neurons fol

57 prevalence and duration of delirium, use of fentanyl and open-label midazolam, and nursing assessmen

58 Patients receiving low doses of fentanyl and propofol adapted to stimuli presented at fi

59 e higher with oxycodone-naloxone followed by fentanyl and tapentadol.

60 pertension increased after administration of fentanyl and/or midazolam (overall aggregate mean Deltaa

61 te epochs before and after administration of fentanyl and/or midazolam for the treatment of episodic

62 receptor desensitization, whereas etorphine, fentanyl, and [D-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin (DAM

63 l and midazolam for sedation, with morphine, fentanyl, and alfentanil as the main analgesics.

64 ntravenous self-administration of oxycodone, fentanyl, and buprenorphine in rats allowed long access

65 Quantitative determination of clenbuterol, fentanyl, and buprenorphine was successfully achieved in

66 Phosphorylation blockage made etorphine, fentanyl, and DAMGO function as morphine in the primary

67 ng dominant-negative GRK2 enabled etorphine, fentanyl, and DAMGO to activate PKCepsilon.

68 Thr370 and Ser375 to Ala) enabled etorphine, fentanyl, and DAMGO to use the PKCepsilon pathway.

69 ly used opioids, including morphine, heroin, fentanyl, and methadone.

70 nding between high efficacy agonists (DAMGO, fentanyl, and morphine) and classic partial agonists (bu

71 Fentanyl anesthesia and mechanical ventilation were cont

72 Isoflurane improves outcome vs. fentanyl anesthesia, in experimental traumatic brain inj

73 after experimental traumatic brain injury in fentanyl-anesthetized rats.

74 a rapid and short-acting synthetic analog of fentanyl, appears to offer clinically significant advant

75 d analgesic responses to morphine but not to fentanyl are moderated by OPRM1 A118G variation, but the

76 ay be one reason cancer patients who receive fentanyl are more satisfied with their pain management.

77 that betaarrestin-biased compounds, such as fentanyl, are more likely to induce respiratory suppress

78 Most intensivists chose fentanyl as their first-line opioid (66%) and midazolam

79 g rats to examine the effects of intravenous fentanyl at doses within the range of possible human int

80 based anesthetic and six patients received a fentanyl-based anesthetic.

81 These results suggest fentanyl be considered as a possible addition to AEP tec

82 Furthermore, fentanyl blockade prevented the significant increase in

83 tions, but this reduction was prevented with fentanyl blockade.

84 a longer duration than that produced by the fentanyl-bupivacaine combination alone.

85 When clonidine is added to a fentanyl-bupivacaine mixture for epidural labor analgesi

86 ified miRNAs, miR-190, was down-regulated by fentanyl but not by morphine.

87 90 (miR-190) in an agonist-dependent manner; fentanyl, but not morphine, decreases the miR-190 level

88 oth [D-Ala2,N-MePhe4, Gly-ol5]enkephalin and fentanyl, but not morphine, produced desensitization of

89 4,Gly5-ol]-enkephalin (DAMGO), methadone, or fentanyl, but not morphine, produced robust internalizat

90 ences were observed among DAMGO, morphine or fentanyl, but these agonists were more efficacious than

91 sic contamination of the parenteral narcotic fentanyl by a health care worker.

92 ted patients, co-sedation with midazolam and fentanyl by constant infusion provides more reliable sed

93 se the designs to generate plant sensors for fentanyl by coupling ligand binding to design stability.

94 This work provides the most detailed fentanyl CAS investigation to date by using orthogonal m

95 Treatment with the MOR agonist fentanyl caused significant activation of ERK1/2 in neur

96 ed between sedation regimens--which included fentanyl, chloral hydrate, pentobarbital, and midazolam

97 -operative day, SYM-2081 (150 or 100 mg/kg), fentanyl citrate (0.04 mg/kg) or vehicle was injected in

98 3-13.1) and the combinations of ketamine and fentanyl citrate (3.2%; OR, 6.5; 95% CI, 2.5-15.2) and k

99 Oral transmucosal fentanyl citrate (OTFC) is undergoing investigation as a

100 Fentanyl citrate is a synthetic opiate analgesic often u

101 apy for reducing the psychoactive effects of fentanyl class drugs.

102 Conversely, after TBI in rats treated with fentanyl, CMRglu increased markedly and bilaterally in C

103 patients are more satisfied with transdermal fentanyl compared with sustained-release oral forms of m

104 hourly drug administration data and measured fentanyl concentrations in plasma collected once daily f

105 in injury and plasma catecholamine and serum fentanyl concentrations measured at the end of both hypo

106 Similarly, serum fentanyl concentrations were higher in hypothermic (vs.

107 , and congestive heart failure most affected fentanyl concentrations.

108 dyspnea was significantly flatter during the fentanyl condition than with placebo.

109 ate were reduced at isotime points under the fentanyl condition, whereas ventilatory efficiency and d

110 rom rats treated with a toxic dose of acetyl fentanyl contained high concentrations of acetyl fentany

111 After 3 d of treatment, morphine and fentanyl decreased the activity of the Ca(2+)/calmodulin

112 Thus, fentanyl decreased the transcription of talin2 and subse

113 vel of its host gene, talin2, suggested that fentanyl decreases the miR-190 level by inhibiting the t

114 ntation that places the N-phenethyl group of fentanyl deep in a crevice between transmembrane (TM) he

115 the binding modes indicates the most potent fentanyl derivatives adopt an extended conformation both

116 The ligand binding modes of a series of fentanyl derivatives are examined using a combination of

117 f fatalities have been linked to overdose of fentanyl derivatives.

118 he metabolic pathways responsible for acetyl fentanyl detoxification and excretion.

119 rformed with intravenous general anesthesia (fentanyl, diazepam, and pancuronium) administered by the

120 ary cultures from beta-arrestin2(-/-) mouse, fentanyl did not decrease the expression of miR-190.

121 cal in the TCR, and ketamine, isoflurane and fentanyl differentially alter the synaptic pathways via

122 epam dose (p = 0.012), and higher cumulative fentanyl dose (p = 0.035) were administered in the delir

123 ce gained significant protection from lethal fentanyl doses.

124 udies are needed to determine if data-driven fentanyl dosing algorithms can improve outcomes for ICU

125 offer clinically significant advantages over fentanyl during outpatient anesthesia.It is reasonable t

126 Up-regulation of miR-339-3p by fentanyl (EC(50)=0.75 nM) resulted from an increase in p

127 Fentanyl effects were blocked by the opioid antagonist n

128 In contrast, the mu-opioid agonist fentanyl elicited a 74 +/- 4% reduction in CGRP levels.

129 pioid exposures (odds ratio, 3.3 per 100 mug fentanyl equivalent/kg; 95% CI, 0.90-16), and paralytic

130 l [CI], 1.03-3.95; P = 0.04), an increase in fentanyl equivalents administered to patients at night (

131 aily (p = .049) and peak (p = .032) doses of fentanyl equivalents, as well as higher mean daily loraz

132 Fentanyl (F), an opioid agonist, increased cerebellar cG

133 orphine (11.6%; 95% CI, 11.2% to 11.9%), and fentanyl family (10.2%; 95% CI, 9.8% to 10.5%).

134 escribed for lung and colorectal cancers and fentanyl family for head and neck cancers (PR, 1.39; 95%

135 tanyl, isoflurane:none, fentanyl:isoflurane, fentanyl:fentanyl, fentanyl:none).

136 the tampering outbreaks, six (75%) involved fentanyl, five (63%) occurred in the United States, and

137 odular' anesthesia that combined injectable (fentanyl-fluanisone/midazolam) and volatile (isoflurane)

138 ns and the mouse hippocampi with morphine or fentanyl for 3 days, seven miRNAs regulated by one or tw

139 n 62 adult cancer patients using transdermal fentanyl for persistent pain.

140 the protein kinase C (PKC)-pathway, whereas fentanyl functions in a beta-arrestin2-dependent manner.

141 analyzed, 129 in alfentanil group and 131 in fentanyl group.

142 Fentanyl worsened lesions in both fentanyl groups' summed neuropathologic scores (P=0.002)

143 Fentanyl has emerged as a recreational drug, often in co

144 The synthetic nature of fentanyl has enabled the creation of dangerous "designer

145 I), in experimental models rats treated with fentanyl have exhibited worse functional outcome and mor

146 erapist had been reported for tampering with fentanyl; his hair sample tested positive for fentanyl.

147 ed analgesia pump (n = 320) or iontophoretic fentanyl hydrochloride (40- microg infusion over 10 minu

148 The fentanyl hydrochloride patient-controlled transdermal sy

149 ntrol conditions and with lumbar intrathecal fentanyl impairing feedback from mu-opioid receptor-sens

150 onditions (CTRL) and with lumbar intrathecal fentanyl impairing lower limb muscle afferent feedback (

151 acebo conditions and with lumbar intrathecal fentanyl impairing spinal mu-opioid receptor-sensitive g

152 Fentanyl in both high and low doses can exacerbate incom

153 were observed between DAMGO and morphine or fentanyl in rat thalamus and SK-N-SH cells and between t

154 or direct quantification of the illicit drug fentanyl in red blood cell extracts.

155 etic, but the basic physiological effects of fentanyl in the brain when taken as a drug of abuse are

156 actors that should be considered when dosing fentanyl in the ICU.

157 P<0.001), were more likely to have received fentanyl in the surgical intensive care unit (odds ratio

158 of JNK and cJun, and that morphine, but not fentanyl, increased the nuclear localization of the phos

159 fferentially by mu-opioid receptor agonists; fentanyl increases NeuroD level by reducing the amount o

160 Fentanyl induced a rapid, dose-dependent decrease in NAc

161 Application of fentanyl induced a reduction in both the frequency and a

162 Fentanyl induced similar oxygen decreases in the basolat

163 Fentanyl-induced beta-arrestin2-mediated ERK phosphoryla

164 gs in the subcutaneous space to confirm that fentanyl-induced brain hypoxia results from decreases in

165 When fentanyl-induced but not morphine-induced ERK phosphoryl

166 xia and a subsequent rise in CO2 that drives fentanyl-induced increases in NAc glucose.

167 Together, these data suggest that fentanyl-induced respiratory depression triggers brain h

168 ngs in the NAc, muscle, and skin showed that fentanyl induces biphasic changes in brain temperature,

169 Aergic effects may be one mechanism by which fentanyl induces bradycardia.

170 The fentanyl infusion was decreased by 1 microg/kg/hr every

171 Cultures of fentanyl infusions from two case patients yielded S. mar

172 isolates from the case patients and from the fentanyl infusions had similar patterns on pulsed-field

173 ventilation and sedation with midazolam and fentanyl infusions.

174 Animals were tested before and after fentanyl injection (100, 500 and 2500 microg g(-1) fish

175 Supplemental analgesia (morphine or fentanyl intravenous boluses) was administered as needed

176 Fentanyl is a potent synthetic opioid used extensively i

177 Fentanyl is an addictive prescription opioid that is ove

178 vivo rodent studies demonstrated that acetyl fentanyl is metabolized by cytochrome P450s to acetyl no

179 However, fentanyl is New Taiwan Dollar (NT$) 103 (approximate US$

180 However, fentanyl is NT$103 (US$ 4) cheaper than alfentanil in ea

181 Fentanyl is well characterized as an anesthetic, but the

182 ic groups (isoflurane:isoflurane, isoflurane:fentanyl, isoflurane:none, fentanyl:isoflurane, fentanyl

183 urane, isoflurane:fentanyl, isoflurane:none, fentanyl:isoflurane, fentanyl:fentanyl, fentanyl:none).

184 s, including propofol, etomidate, midazolam, fentanyl, ketamine, and nitrous oxide.

185 [MD] 2 micrograms kg-1 min-1), or high-dose fentanyl (LD 800 micrograms kg-1, MD 32 micrograms kg-1

186 control (N2O plus 0.4% halothane), low dose fentanyl (loading dose [LD] 50 micrograms kg-1, maintena

187 uced impact of side effects with transdermal fentanyl may be one reason cancer patients who receive f

188 midazolam (102 mg/d vs 82 mg/d; P = .04) and fentanyl (median [IQR], 550 [50-1850] vs 260 [0-1400]; P

189 elective micro-antagonist CTOP abolished the fentanyl-mediated inhibition of GABAergic IPSCs.

190 rast, a second class of mu-opioids including fentanyl, methadone, and oxycodone produced acute analge

191 Common drugs implicated included propofol, fentanyl, metoprolol, lorazepam, hydralazine, and furose

192 of alfentanil, midazolam and propofol versus fentanyl, midazolam and propofol in 272 outpatients unde

193 d SK-N-SH cells, followed by (in rank order) fentanyl = morphine > > buprenorphine.

194 sics: oxycodone, hydrocodone, hydromorphone, fentanyl, morphine, and tramadol.

195 er cardioplegia alone or delta-opiate drugs (fentanyl, morphine, buprenorphine, pentazocine) followed

196 age, sex, PMA, dose of analgesics/sedatives (fentanyl, morphine, midazolam), mechanical ventilation,

197 Intravenous infusion narcotics (fentanyl, morphine, or hydromorphone) were used more fre

198 sociated with the synthesis of the analgesic fentanyl, N-(1-phenylethylpiperidin-4-yl)-N-phenylpropan

199 ing continuous infusions of midazolam and/or fentanyl; no changes in ventilator settings, nutritional

200 one, fentanyl:isoflurane, fentanyl:fentanyl, fentanyl:none).

201 Neither mu-(morphine and fentanyl) nor delta- ([D-Pen2, D-Pen5]enkephalin- and SN

202 Therefore, the effect of fentanyl on GABAergic neurotransmission to parasympathet

203 rmore, the inhibitory effect of subcutaneous fentanyl on mechanical nociception was eliminated by CTA

204 gnaling pathway that mediates the effects of fentanyl on miR-190 expression.

205 anisms of action of ketamine, isoflurane and fentanyl on the synaptic TCR responses in both neurones

206 milarly abolished the effect of subcutaneous fentanyl on thermal nociception of the hindpaw but not t

207 activated by opioid agonist treatment (10 nM fentanyl or 10 muM morphine), a specific effect blocked

208 The patients who received epidural fentanyl or bupivacaine prior to surgical incision (pree

209 this model and ibuprofen did not potentiate fentanyl or morphine analgesia.

210 inase activation was not increased by either fentanyl or morphine treatment in neurons from wild type

211 After 15 min of fentanyl or sham infusion trimethaphan 0.5 mg was given

212 ere randomly assigned to receive intrathecal fentanyl or systemic hydromorphone at the first request

213 at animals that self-administered oxycodone, fentanyl, or heroin, but not buprenorphine had similar p

214 ropoxyphene, tramadol, morphine, meperidine, fentanyl, or hydroxycodone, either alone or in combinati

215 , rats were randomized to 1 h of isoflurane, fentanyl, or no additional anesthesia, creating 6 anesth

216 Epidural bupivacaine, epidural fentanyl, or no epidural drug was administered prior to

217 either [D-Ala2,N-MePhe4,Gly-ol5]-enkephalin, fentanyl, or sufentanyl, produced a GRK3- and beta-arr 2

218 New pharmacologic modalities such as the fentanyl oralet for sedation of children are discussed a

219 creased in the order etorphine >> morphine > fentanyl = oxymorphine > butorphanol = oxycodone = nalbu

220 oncentration (P < .0001), concomitant use of fentanyl (P = .008) and ketoconazole (P = .03), and age

221 nificantly after administration of high-dose fentanyl (p = 0.02), low-dose midazolam (p = 0.006), and

222 e to prescribe methadone, recognize risks of fentanyl patches, titrate cautiously, and reduce doses b

223 Fentanyl patients also experienced a significantly lower

224 % of patients (233/316) who used transdermal fentanyl PCA and 76.9% of patients (246/320) who used in

225 ty of illness was marginally associated with fentanyl pharmacokinetics but did not improve the model

226 In this study, fentanyl pharmacokinetics during critical illness were s

227 s model implemented by NONMEM, we found that fentanyl pharmacokinetics were best described by a two-c

228 ow-dose midazolam (p = 0.006), and high-dose fentanyl plus low-dose midazolam (0.007).

229 In rats pretreated with fentanyl, post-traumatic isoflurane failed to affect fun

230 and MWM performances than rats treated with fentanyl pre- and any treatment post-TBI.

231 Rats receiving fentanyl pre- and post-TBI had the worst CA1 neuronal su

232 mproved CA3 neuronal survival vs. rats given fentanyl pre- and post-TBI.

233 er CA3 neuronal survival than rats receiving fentanyl pre- and post-TBI.

234 e on the toxicology and metabolism of acetyl fentanyl precludes its detection in human samples.

235 timulated [(35)S]GTPgammaS binding following fentanyl pretreatment was not blocked by JNK inhibition.

236 d and tested against CAS profiles from crude fentanyl products deposited and later extracted from two

237 dermal system using iontophoresis to deliver fentanyl provided postsurgical pain control equivalent t

238 protocol 2, five control and five high-dose fentanyl rats were treated identically except that post-

239 re made in somatosensory cortical barrels of fentanyl-sedated rats.

240 ailability unmasked genotypic differences in fentanyl sensitivity.

241 The unique binding mode(s) proposed for the fentanyl series may, in part, explain the difficulties e

242 Although fentanyl significantly depresses heart rate, the mechani

243 SYM-2081 and fentanyl significantly reduced these responses (p<0.05).

244 Etonitazene and fentanyl stimulated the in vivo phosphorylation of multi

245 Purpose Fentanyl sublingual tablets (FST) are a potentially usef

246 elationships between ligand conformation and fentanyl substitution and to generate probable "bioactiv

247 al model capable of predicting the method of fentanyl synthesis was validated and tested against CAS

248 synthesis methods, all previously published fentanyl synthetic routes or hybrid versions thereof, we

249 refore, we tested the effects of transdermal fentanyl (TDF) in patients with moderate-to-severe OA pa

250 s reduced by morphine, but maintained during fentanyl treatment.

251 evelopment was 67 +/- 10% greater during the fentanyl trial (P < 0.01).

252 ed 8 and 10% lower, respectively, during the fentanyl trial and these differences progressively dimin

253 cebo, significant hypoventilation during the fentanyl trial was indicated by the 9% lower V(E)/V(CO(2

254 y and bilaterally in CA1 and CA3 (p<0.05 vs. fentanyl uninjured), but not ipsilateral parietal cortex

255 Our newly developed fentanyl vaccine and analytical methods may assist in th

256 The starting infusion rate for subcutaneous fentanyl varied from 5 to 9 microg/kg/hr (mean, 7.1 +/-

257 Early patient discontinuations (25.9% fentanyl vs 25.0% morphine; P =.78) and last pain intens

258 P =.78) and last pain intensity scores (32.7 fentanyl vs 31.1 morphine on the VAS; P =.45) were not d

259 3 hippocampus after TBI in rats treated with fentanyl vs. isoflurane anesthesia.

260 nd more CA1 hippocampal death after TBI with fentanyl vs. isoflurane anesthesia.

261 Uninjured rats treated with fentanyl vs. isoflurane showed 35-45% higher CMRglu in a

262 lu was nearly two times greater after TBI in fentanyl vs. isoflurane treated rats (p<0.05).

263 glu), may account for detrimental effects of fentanyl vs. isoflurane.

264 CMD was 9 +/- 3% higher at end-exercise with fentanyl vs. placebo (P < 0.05).

265 reater (-44 +/- 2% vs. -34 +/- 2%) following fentanyl vs. placebo.

266 In contrast, ERK1/2 activation by fentanyl was not evident in neurons from GRK3-/- mice or

267 Lumbar intrathecal fentanyl was used to attenuate the central projection of

268 To rule out a direct central effect of fentanyl, we documented unchanged resting cardioventilat

269 ditionally, greater amounts of lorazepam and fentanyl were administered to patients with delirium.

270 Plasma levels of fentanyl were higher in patients with clinical coma (3.7

271 ut the analgesic actions of heroin, M6G, and fentanyl were markedly diminished in the radiant heat ta

272 Patients who received transdermal fentanyl were more satisfied overall with their pain med

273 In contrast, the behavioral effects of fentanyl were neither genotype-dependent nor affected by

274 e the fact that cancer patients who received fentanyl were significantly older (P < .001) and had sig

275 atients required prolonged administration of fentanyl with or without midazolam during mechanical ven

276 Subcutaneous fentanyl with or without midazolam was administered to n

277 Fentanyl worsened lesions in both fentanyl groups' summe

278 We tested the hypothesis that fentanyl would worsen ischemia-induced brain damage.